Near-total Reduction in Verapamil Bioavailability by Rifampin
| Autor: | Rick A. Barbarash, Randal L. Batenhorst, George T. Kondos, Jerry L. Bauman, James H. Fischer |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Pulmonary and Respiratory Medicine
business.industry Norverapamil Pharmacology Drug interaction Critical Care and Intensive Care Medicine Bioavailability chemistry.chemical_compound Route of administration Pharmacokinetics chemistry Oral administration cardiovascular system medicine Verapamil Cardiology and Cardiovascular Medicine business Volunteer medicine.drug |
| Zdroj: | Chest. 94:954-959 |
| ISSN: | 0012-3692 |
| Popis: | We evaluated the significance of the interaction between rifampin and verapamil in six volunteers who received single doses of verapamil, 10 mg intravenously (IV), then 120 mg orally two days later. Subjects were then given rifampin, 600 mg orally every day for 15 days. After 13 and 15 days of rifampin therapy, the IV and oral doses of verapamil were repeated. Electrocardiograms (ECG) were done and serum verapamil and norverapamil concentrations measured before and for 12 h after each dose. For IV verapamil, there was a small decrease in area under the serum concentration-time curve and an increase in clearance after rifampin therapy (p PR ). For oral verapamil, there were marked decreases in peak concentration, AUC, oral bioavailability (all p PR (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|